NDAORALTABLET
Approved
Mar 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ALDOCLOR-150 (chlorothiazide; methyldopa) by Merck & Co. is clinical pharmacology: the mechanism of the antihypertensive effect of thiazides is unknown. Approved for pregnancy, just, heart failure and 2 more indications. First approved in 1968.
Drug data last refreshed 26m ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALDOCLOR-150 is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and methyldopa (a central-acting antihypertensive) indicated for hypertension management. Chlorothiazide promotes sodium and chloride excretion in the distal renal tubule, while methyldopa acts centrally to reduce blood pressure. This combination product targets patients requiring dual antihypertensive therapy.
LOE Approaching
Product is approaching loss of exclusivity; brand team is likely in maintenance or transition mode with reduced headcount and marketing investment focused on existing prescriber relationships.
Mechanism of Action
CLINICAL PHARMACOLOGY: The mechanism of the antihypertensive effect of thiazides is unknown. Chlorothiazide does not usually affect normal blood pressure. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are…
Indications (5)
Worked on ALDOCLOR-150 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.